Your browser doesn't support javascript.
Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.
Birabaharan, Morgan; Martin, Thomas C S.
  • Birabaharan M; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address: mbirabaharan39@gmail.com.
  • Martin TCS; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; San Diego Veterans Affairs Healthcare System, San Diego, CA, USA.
Am J Emerg Med ; 61: 235.e5-235.e6, 2022 11.
Article in English | MEDLINE | ID: covidwho-2075854
ABSTRACT
The return of COVID-19 symptoms after Nirmatrelvir/Ritonavir (Nm/R) treatment is being increasingly reported. Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention. Here we present a male veteran reporting rebound symptoms who was found to be hypoxic with pulmonary emboli. Our case highlights the need to evaluate known complications of SARS-CoV-2 including venous thromboembolism in patients reporting recurring symptoms. Further, cases of severe rebound phenomenon should continue to be reported by clinicians to better appreciate the use of the Nm/R during the Omicron wave and among vaccinated persons.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Embolism / COVID-19 Type of study: Case report / Experimental Studies Topics: Vaccines / Variants Limits: Humans / Male Language: English Journal: Am J Emerg Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Embolism / COVID-19 Type of study: Case report / Experimental Studies Topics: Vaccines / Variants Limits: Humans / Male Language: English Journal: Am J Emerg Med Year: 2022 Document Type: Article